SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
SAB Biotherapeutics reported positive Phase 1 data for SAB-142, showing C-peptide preservation in all treated T1D participants with a super responder profile in 3 of 4. Participants also showed improved glycemic control, with mean time in range increasing from 73% at baseline to 85% at Day 120.
Key figures
- Drug Name
- SAB-142
- Phase Of Trial
- Phase 1
- Cohort n
- 6
- Placebo n
- 2
- Treated n
- 4
- Time in range day 120 percent
- 85
- Time in range baseline percent
- 73
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.